TP53 and neoplasm: The number of novel missense variants has not increased significantly for several years now [50], indicating that a saturation plateau has been reached with the discovery of all potential p53 variants that sustain a loss of their tumor suppressor functions (Supplementary Figure S2 available online at http://bib.oxfordjournals.org/).